ExeVir receives EIB risk finance for multiple COVID-19 nanobody – European Biotechnology News
09.01.2023 by tg With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012. With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3% of the population of Western … Read more